Aitia
Jeanne Latourelle has a diverse work experience in the field of precision medicine and research. Jeanne is currently serving as the Senior Vice President of Precision Medicine at Aitia since October 2021. Prior to that, they had a long association with Boston University School of Medicine, where they held various roles including Research Assistant Professor, Research Instructor, and Project Manager. During their time at Boston University, their research focused on epidemiology of complex diseases, statistical analysis, and integration of genetic and genomic datasets for disease etiology, therapeutic target identification, and biomarker development.
In addition to their work at Boston University, Jeanne Latourelle has also worked at GNS Healthcare, where they held multiple positions related to precision medicine. Jeanne served as the Vice President, Executive Director, and Director of Precision Medicine at different times from 2017 to 2021. Jeanne also held the positions of Principal Scientist and Senior Scientist at GNS Healthcare. Jeanne'swork at GNS Healthcare involved utilizing advanced data analysis techniques to uncover insights and drive innovation in precision medicine.
Overall, Jeanne Latourelle's work experience showcases their expertise in precision medicine, epidemiology, statistical analysis, and integration of genetic and genomic information for disease research and biomarker development.
Jeanne Latourelle received their B.S. in Biomedical Engineering from Boston University in 1998. Jeanne then pursued their M.S. in Biomedical Engineering from the Massachusetts Institute of Technology from 1998 to 2000. Subsequently, they enrolled at the Boston University School of Public Health and completed their D.Sc. in Epidemiology from 2004 to 2009.
This person is not in any offices
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.